Dianthus Therapeutics Inc
NASDAQ:DNTH

Watchlist Manager
Dianthus Therapeutics Inc Logo
Dianthus Therapeutics Inc
NASDAQ:DNTH
Watchlist
Price: 41.32 USD -0.72%
Market Cap: 1.8B USD

Wall Street
Price Targets

DNTH Price Targets Summary
Dianthus Therapeutics Inc

Wall Street analysts forecast DNTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DNTH is 68.77 USD with a low forecast of 46.46 USD and a high forecast of 105 USD.

Lowest
Price Target
46.46 USD
12% Upside
Average
Price Target
68.77 USD
66% Upside
Highest
Price Target
105 USD
154% Upside
Dianthus Therapeutics Inc Competitors:
Price Targets
300142
Walvax Biotechnology Co Ltd
36% Downside
TRDA
Entrada Therapeutics Inc
65% Upside
OCC
Orthocell Ltd
30% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
66% Upside
6628
Transcenta Holding Limited
606% Upside
MRSN
Mersana Therapeutics Inc
18% Upside
688520
Sinocelltech Group Ltd
29% Upside
2142
Hbm Holdings Ltd
12% Upside

Revenue
Forecast

Revenue Estimate
Dianthus Therapeutics Inc

The compound annual growth rate of Dianthus Therapeutics Inc's revenue for the next 4 years is 53%.

N/A
Past Growth
53%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Dianthus Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Dianthus Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-92%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DNTH's stock price target?
Price Target
68.77 USD

According to Wall Street analysts, the average 1-year price target for DNTH is 68.77 USD with a low forecast of 46.46 USD and a high forecast of 105 USD.

What is Dianthus Therapeutics Inc's Revenue forecast?
Projected CAGR
53%

The compound annual growth rate of Dianthus Therapeutics Inc's revenue for the next 4 years is 53%.

Back to Top